Literature DB >> 26206424

Effects of androgen on immunohistochemical localization of androgen receptor and Connexin 43 in mouse ovary.

Mei Yang1, Jianhua Li2, Yulin An3, Shuiwen Zhang4.   

Abstract

Androgens have essential roles in the regulation of follicular development and female fertility. Androgen excess is the leading defect in polycystic ovary syndrome (PCOS) patients and involved in the ovarian dysfunction. The aim of this study was to elucidate the regarding regulatory role of androgen in the follicular development of female mouse. Immunohistochemical staining and Western blot analyses were performed to detect androgen receptor (AR) and Connexin 43 (Cx43) expression in ovaries from both control and testosterone-treated group mice. In this study, localizations of AR and Cx43 were dramatically altered in testosterone-treated mouse ovaries. In addition, AR expression was significantly increased, whereas Cx43 expression was markedly decreased after testosterone treatment. Alterations of AR and Cx43 expression by testosterone with concomitant reduction of MII oocytes. Overall, these results suggest the involvement of androgen in the regulation of AR and Cx43 localizations in mouse ovary. Alterations of AR and Cx43 expression by testosterone may affect normal folliculogenesis. Together these findings will enable us to begin understanding the important roles of AR and Cx43 actions in the regulation of follicular development, as well as providing insights into the role of AR and Cx43 actions in the androgen-associated reproductive diseases such as PCOS.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Androgen; Androgen receptor; Connexin 43; Ovary

Mesh:

Substances:

Year:  2015        PMID: 26206424     DOI: 10.1016/j.tice.2015.06.003

Source DB:  PubMed          Journal:  Tissue Cell        ISSN: 0040-8166            Impact factor:   2.466


  8 in total

Review 1.  Impact of Exogenous Testosterone on Reproduction in Transgender Men.

Authors:  Molly B Moravek; Hadrian M Kinnear; Jenny George; Jourdin Batchelor; Ariella Shikanov; Vasantha Padmanabhan; John F Randolph
Journal:  Endocrinology       Date:  2020-03-01       Impact factor: 4.736

2.  Developmental Programming: Gestational Exposure to Excess Testosterone Alters Expression of Ovarian Matrix Metalloproteases and Their Target Proteins.

Authors:  Muraly Puttabyatappa; Ashleigh Irwin; Jacob D Martin; Makeda Mesquitta; Almudena Veiga-Lopez; Vasantha Padmanabhan
Journal:  Reprod Sci       Date:  2017-03-16       Impact factor: 3.060

Review 3.  Pathology of hyperandrogenemia in the oocyte of polycystic ovary syndrome.

Authors:  Neil R Chappell; William E Gibbons; Chellakkan S Blesson
Journal:  Steroids       Date:  2022-02-18       Impact factor: 2.668

4.  Ovarian follicular dynamics after aromatizable or non aromatizable neonatal androgenization.

Authors:  Gabriel Anesetti; Rebeca Chávez-Genaro
Journal:  J Mol Histol       Date:  2016-08-19       Impact factor: 2.611

5.  A mouse model to investigate the impact of testosterone therapy on reproduction in transgender men.

Authors:  H M Kinnear; E S Constance; A David; E E Marsh; V Padmanabhan; A Shikanov; M B Moravek
Journal:  Hum Reprod       Date:  2019-10-02       Impact factor: 6.918

6.  Androgen effect on connexin expression in the mammalian female reproductive system: A systematic review.

Authors:  Datu Agasi Mohd Kamal; Siti Fatimah Ibrahim; Mohd Helmy Mokhtar
Journal:  Bosn J Basic Med Sci       Date:  2020-08-03       Impact factor: 3.363

7.  Embryos from polycystic ovary syndrome patients with hyperandrogenemia reach morula stage faster than controls.

Authors:  Neil Ryan Chappell; Maya Barsky; Jaimin Shah; Mary Peavey; Liubin Yang; Haleh Sangi-Haghpeykar; William Gibbons; Chellakkan Selvanesan Blesson
Journal:  F S Rep       Date:  2020-09-02

8.  Effects of Electroacupuncture on Ovarian Expression of the Androgen Receptor and Connexin 43 in Rats with Letrozole-Induced Polycystic Ovaries.

Authors:  Ge Xu; Andong Zhang; Jiandang Liu; Xi Wang; Jiwei Feng; Yuelai Chen
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-14       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.